Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy characterized by rapidly progressive weakness and variable recovery trajectories. Although many patients regain functional independence after the acute phase, increasing evidence suggests that long-term sequelae such as fatigue, pain, residual disability, and reduced health-related quality of life are common and frequently under-recognized. However, contemporary evidence on long-term outcomes after GBS remains dispersed across multiple study designs and populations, making an updated synthesis clinically relevant. This systematic review aimed to evaluate long-term outcomes reported at or beyond six months after GBS onset, focusing on functional recovery, persistent symptoms, and patient-reported quality of life. A systematic search of PubMed was conducted for studies published between January 2014 and November 2025 using predefined search terms related to GBS and long-term outcomes. Studies reporting outcomes beyond six months after disease onset were included, encompassing cohort studies, clinical trials with follow-up, qualitative studies, and systematic reviews. Due to heterogeneity in study design, outcome measures, and follow-up duration, findings were synthesized narratively. Across the included literature, most patients demonstrated substantial neurological recovery within the first year; however, a clinically meaningful proportion continued to experience persistent symptoms beyond one to three years. Fatigue and neuropathic pain were among the most frequently reported long-term sequelae and were major contributors to impaired quality of life despite apparent motor recovery. Residual functional limitations, participation restrictions, and psychosocial impacts were also commonly reported. Factors associated with poorer long-term outcomes included older age, severe disease at presentation, requirement for mechanical ventilation, autonomic dysfunction, and axonal electrophysiological patterns. These findings highlight that recovery from GBS is often incomplete despite improvement in neurological function. Long-term follow-up incorporating rehabilitation, symptom-directed management, and patient-reported outcome measures may be essential to better address persistent morbidity and optimize quality of life in GBS survivors.
Hussain et al. (Mon,) studied this question.